Summary
The translation of analgesic efficacy seen in preclinical pain models into the clinic is problematic and is associated with a number of factors that may result in the failure of clinical trials to detect the effect of investigational therapeutic agents. The use of translational pain biomarkers in phase I trials can potentially reduce some of these risks by measuring the interaction between the drug and its target (termed target engagement) in humans. To serve this purpose, sensory tests and other measures of pharmacological activity in nociceptive pathways need to be identified, based on the preclinical profile of the drug being tested and the feasibility of human assessments. Here we discuss some examples to assess the utility of sensory and related pain biomarkers in the early phase of evaluation of novel analgesics for confirmation of target engagement in humans. The emphasis is on the TRPV1 antagonists, but some other target mechanisms are also discussed in examining the validity of this approach.
Article PDF
Similar content being viewed by others
References
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3: 711–715.
Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs 2007;8: 41–53.
Arendt-Nielsen L, Yarnitsky D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain 2009;10: 556–572.
Huntjens DR, Spalding DJ, Danhof M, Delia Pasqua OE. Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br J Pharmacol 2006;148: 396–404.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389: 816–824.
Szallasi A, Appendino G. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers: are we putting the cart before the horse? J Med Chem 2004;47: 2717–2723.
Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 2009;78: 211–216.
Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 2009;14: 56–67.
Hu HJ, Bhave G, Gereau RW. Prostaglandin and protein kinase A-dependent modulation of vanilloid receptor function by metabotropic glutamate receptor 5: potential mechanism for thermal hyperalgesia. J Neurosci 2002;22: 7444–7452.
Gunthorpe MJ, Benham CD, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002;23: 183–191.
Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 2006;12: 545–554.
Chizh BA, O’Donnell MB, Napolitano A, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007;132: 132–141.
Gunthorpe MJ, Hannan SL, Smart D, et al. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007; 321: 1183–1192.
Davis JB, Rami HK, Stevens AJ. SB-705498, a clinical candidate with antagonist activity at TRPV1 and efficacy in a wide range of preclinical pain models. Abstr Soc Neurosci 2005:364.2 (abstract; available at http://www.sfn.org).
LaMotte RH, Lundberg LE, Torebjörk HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 1992;448: 749–764.
LaMotte RH, Shain CN, Simone DA, Tsai EF. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol 1991;66: 190–211.
Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 1989;38: 99–107.
Sang CN, Gracely RH, Max MB, Bennett GJ. Capsaicin-evoked mechanical allodynia and hyperalgesia cross nerve territories: evidence for a central mechanism. Anesthesiology 1996;85: 491–496.
Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain 1998;76: 317–325.
Benrath J, Gillardon F, Zimmermann M. Differential time courses of skin blood flow and hyperalgesia in the human sunburn reaction following ultraviolet irradiation of the skin. Eur J Pain 2001;5: 155–167.
Gustorff B, Anzenhofer S, Sycha T, Lehr S, Kress HG. The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg 2004;98: 173–177.
Yeomans DC, Proudfit HK. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. Pain 1996;68: 141–150.
Geber C, Fondel R, Krämer HH, et al. Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain. J Pain 2007;8: 503–514.
Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993;100: 35S-41S.
Benrath J, Eschenfelder C, Zimmerman M, Gillardon F. Calcitonin gene-related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet irradiation. Eur J Pharmacol 1995;293: 87–96.
Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000;288: 306–313.
Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000;405: 183–187.
García-Martinez C, Humet M, Planells-Cases R, et al. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc Natl Acad Sci U S A 2002;99: 2374–2379.
Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001;24: 487–517.
Krause JE, Chenard BL, Cortright DN. Transient receptor potential ion channels as targets for the discovery of pain therapeutics. Curr Opin Investig Drugs 2005;6: 48–57.
Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 2008;14: 32–41.
Weidner C, Klede M, Rukwied R, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin: a microdialysis study. J Invest Dermatol 2000;115: 1015–1020.
Sauerstein K, Klede M, Hilliges M, Schmelz M. Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin. J Physiol 2000;529: 803–810.
Schmelz M, Michael K, Weidner C, Schmidt R, Torebjörk HE, Handwerker HO. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 2000;11: 645–648.
Klede M, Clough G, Lischetzki G, Schmelz M. The effect of the nitric oxide synthase inhibitor N-nitro-l-arginine-methyl ester on neuropeptide-induced vasodilation and protein extravasation in human skin. J Vasc Res 2003;40: 105–114.
Koppert W, Dern SK, Sittl R, Albrecht S, Schüttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001;95: 395–402.
Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M. Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 2000;85: 217–224.
Klede M, Handwerker HO, Schmelz M. Central origin of secondary mechanical hyperalgesia. J Neurophysiol 2003;90: 353–359.
Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005;(4):CD003345.
Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324: 416–421.
de Hoon J, de Lepeleire I, Hickey L, et al. Inhibition of capsaicin-induced increase in dermal microvascular blood flow by the oral CGRP antagonist, MK-0974. Cephalalgia 2007;27: 738–739 (abstract).
Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007; 28: 580–587.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chizh, B.A., Sang, C.N. Use of sensory methods for detecting target engagement in clinical trials of new analgesics. Neurotherapeutics 6, 749–754 (2009). https://doi.org/10.1016/j.nurt.2009.08.005
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2009.08.005